

ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION SECURES ETHICS APPROVAL FOR PILOT CLINICAL TRIAL

Highlights:

- *Ethics approval received for the Pilot Clinical Trial of EMvision's Brain Scanner*
- *Study to be conducted at leading research centre Princess Alexandra Hospital, Brisbane*
- *EMvision is currently finalising hardware and user interface software elements of its prototype brain scanner, in preparation for fabrication of the clinical trial units*
- *Study timeframe remains on track and is expected to commence in second half CY2019*

EMvision Medical Devices Limited (ASX: EMV) ("EMvision" or the "Company") is pleased to announce the receipt of Human Research Ethics Committee (HREC) approval from Metro South Health, for its planned pilot clinical trial for the brain scanner program at the Princess Alexandra Hospital in Brisbane.

Ethics approval is a crucial step in the conduct of clinical research and the HREC plays a central role in the ethical oversight of research involving human participants. This includes consideration of the scientific design of the study, how participants will be recruited, the care and protection from harm of research participants and protection of research participants' confidentiality.

The study is designed to obtain imaging data from participants with diagnosed stroke, with confirmatory CT and/or MRI scans, to refine the algorithms for EMvision's brain scanner. The study is a single-centre, two-group observational study of participants with a diagnosed stroke. Up to twenty (20) participants will be enrolled in each group: haemorrhagic stroke (group A) and ischemic stroke (group B) with up to 30 patients in total. No intervention or modification to the usual hospital based treatment of stroke is proposed as part of this trial.

EMvision Chief Executive Officer, Dr Ron Weinberger commented: "We are pleased to have secured Ethics Approval for our pilot clinical trial at the Princess Alexandra Hospital, Brisbane. The Princess Alexandra Hospital is a major medical research precinct and home to some of the world's best researchers and health professionals."

Dr Weinberger continued: "There is a significant unmet need for point of care diagnostics for stroke and traumatic brain injury and we look forward to advancing the clinical development of the EMvision brain scanner, with expected commencement of the study in second half 2019."

Receipt of ethics approval follows the successful completion of healthy human volunteer trials, which demonstrated device safety and usability. EMvision is currently finalising the brain scanner's hardware and user interface software elements, in preparation for fabrication of the clinical trial units. EMvision will provide updates on device development progress and the clinical study program in due course.

PRODUCT PIPELINE

BRAIN SCANNER

Identify and monitor stroke and traumatic brain injury



TORSO SCANNER

Identify the severity and monitor the progression of liver disease



[ENDS]

For further information, media or investor enquires, please contact:

Michael Wills
 Investor & Media Relations
 +61 468 385 208
 michael@spring-communications.com.au

Scott Kirkland
 Executive Director
 +61 2 8667 5337
 skirkland@emvision.com.au

About EMvision Medical Devices

EMvision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997.